(Q28371512)

English

ALK ALK Fusion G1269A

genetic variant

ALK FUSION G1269A
ALK FUSION GLY1269ALA
RS1057519781

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

chromosome

human chromosome 2

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

genomic start

29432682

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

genomic end

29432682

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

positive therapeutic predictor for

ceritinib

medical condition treated

non-small-cell lung carcinoma

determination method

CIViC evidence level D

rating

CIViC 3-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1342

stated in

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

ceritinib

medical condition treated

cancer

determination method

CIViC evidence level D

rating

CIViC 2-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1355

stated in

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

AP-26113

medical condition treated

cancer

determination method

CIViC evidence level D

rating

CIViC 2-star trust rating

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1353

stated in

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

negative therapeutic predictor for

alectinib

determination method

CIViC evidence level D

rating

CIViC 3-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/1354

stated in

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

Identifiers

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

dbSNP Reference SNP number

1 reference

ENST00000389048.3:c.3806G>C

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

NC_000002.11:g.29432682C>G

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

NM_004304.4:c.3806G>C

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

NP_004295.2:p.Gly1269Ala

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/552

(Q28371512)

ALK ALK Fusion G1269A

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)